226 related articles for article (PubMed ID: 24995447)
21. Laboratory diagnosis of bleeding disorders. Basic screening tests.
Palmer RL
Postgrad Med; 1984 Dec; 76(8):137-42, 147-8. PubMed ID: 6334288
[TBL] [Abstract][Full Text] [Related]
22. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing.
Tripodi A; Chantarangkul V; Mannucci PM
Br J Haematol; 2009 Oct; 147(1):77-82. PubMed ID: 19659548
[TBL] [Abstract][Full Text] [Related]
23. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
24. Effect of drawing a discard tube on PT and APTT results in healthy adults.
Bamberg R; Cottle JN; Williams JC
Clin Lab Sci; 2003; 16(1):16-9. PubMed ID: 12587654
[TBL] [Abstract][Full Text] [Related]
25. Coagulation in Liver Disease.
Hoffman M
Semin Thromb Hemost; 2015 Jul; 41(5):447-54. PubMed ID: 26049068
[TBL] [Abstract][Full Text] [Related]
26. Utilization of coagulation assays in clinical therapeutics.
Peters GL; Erwin PB; Pitlick MK; Stacy ZA
Pharmacotherapy; 2013 Nov; 33(11):1214-22. PubMed ID: 23686890
[TBL] [Abstract][Full Text] [Related]
27. Coagulation studies in preoperative neurosurgical patients.
Schramm B; Leslie K; Myles PS; Hogan CJ
Anaesth Intensive Care; 2001 Aug; 29(4):388-92. PubMed ID: 11512650
[TBL] [Abstract][Full Text] [Related]
28. Interactions of bexarotene (LGD1069, Targretin) with the coagulation system.
Hespel A; Mejdoubi-Charef N; Yous S; Courty J; Papy-Garcia D; Charef S
Cancer Chemother Pharmacol; 2011 Oct; 68(4):847-54. PubMed ID: 21229355
[TBL] [Abstract][Full Text] [Related]
29. Laboratory coagulation parameters in extremely premature infants born earlier than 27 gestational weeks upon admission to a neonatal intensive care unit.
Neary E; Okafor I; Al-Awaysheh F; Kirkham C; Sheehan K; Mooney C; Foran A; Corcoran JD; Ni Ainle F; Cotter M; McCallion N
Neonatology; 2013; 104(3):222-7. PubMed ID: 24030102
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic uses of the activated partial thromboplastin time and prothrombin time.
Suchman AL; Griner PF
Ann Intern Med; 1986 Jun; 104(6):810-6. PubMed ID: 3706933
[TBL] [Abstract][Full Text] [Related]
31. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery.
Reich DL; Yanakakis MJ; Vela-Cantos FP; DePerio M; Jacobs E
Anesth Analg; 1993 Oct; 77(4):673-9. PubMed ID: 8214648
[TBL] [Abstract][Full Text] [Related]
32. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a bench-top coagulation analyzer for measurement of prothrombin time, activated partial thromboplastin time, and fibrinogen concentrations in healthy dogs.
Mineo HK; Garabed RB
Am J Vet Res; 2007 Dec; 68(12):1342-7. PubMed ID: 18052739
[TBL] [Abstract][Full Text] [Related]
34. [Monitoring of coagulation status in the physician's laboratory].
Marbet GA
Ther Umsch; 1995 May; 52(5):343-9. PubMed ID: 7770821
[TBL] [Abstract][Full Text] [Related]
35. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
36. Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality.
Wagenaar JF; Goris MG; Partiningrum DL; Isbandrio B; Hartskeerl RA; Brandjes DP; Meijers JC; Gasem MH; van Gorp EC
Trop Med Int Health; 2010 Feb; 15(2):152-9. PubMed ID: 20002620
[TBL] [Abstract][Full Text] [Related]
37. Properties of optical data from activated partial thromboplastin time and prothrombin time assays.
Braun PJ; Givens TB; Stead AG; Beck LR; Gooch SA; Swan RJ; Fischer TJ
Thromb Haemost; 1997 Sep; 78(3):1079-87. PubMed ID: 9308757
[TBL] [Abstract][Full Text] [Related]
38. Routine use of the prothrombin and partial thromboplastin times.
Erban SB; Kinman JL; Schwartz JS
JAMA; 1989 Nov; 262(17):2428-32. PubMed ID: 2795828
[TBL] [Abstract][Full Text] [Related]
39. Effects of reagent and instrument on prothrombin times, activated partial thromboplastin times and patient/control ratios.
Naghibi F; Han Y; Dodds WJ; Lawrence CE
Thromb Haemost; 1988 Jun; 59(3):455-63. PubMed ID: 3187932
[TBL] [Abstract][Full Text] [Related]
40. Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
Santoro RC; Molinari AC; Leotta M; Martini T
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
